Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

638 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Integrated Exposure-Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis.
Briggs E, Kamal MA, Kosloski MP, Linsmeier I, Jusko N, Dolphin N, Chittenden J, Simpson EL, Paller AS, Siegfried EC, Shumel B, Levit NA, Bansal A, Davis JD, Chapel S, Smith DE, Huniti N. Briggs E, et al. Among authors: paller as. Pharm Res. 2023 Nov;40(11):2653-2666. doi: 10.1007/s11095-023-03616-8. Epub 2023 Dec 11. Pharm Res. 2023. PMID: 38082089 Free PMC article.
Phenotypic and Endotypic Determinants of Atopic Dermatitis Severity From the Atopic Dermatitis Research Network (ADRN) Registry.
Simpson EL, De Benedetto A, Boguniewicz M, Ong PY, Lussier S, Villarreal M, Schneider LC, Paller AS, Guttman-Yassky E, Hanifin JM, Spergel JM, Barnes KC, David G, Austin B, Leung DYM, Beck LA. Simpson EL, et al. Among authors: paller as. J Allergy Clin Immunol Pract. 2023 Aug;11(8):2504-2515. doi: 10.1016/j.jaip.2023.04.052. Epub 2023 May 12. J Allergy Clin Immunol Pract. 2023. PMID: 37182563 Free PMC article.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 16-Week Trial to Evaluate the Efficacy and Safety of FB-401 in Children, Adolescents, and Adult Subjects (Ages 2 Years and Older) with Mild-to-Moderate Atopic Dermatitis.
Jacobson ME, Myles IA, Paller AS, Eichenfield LF, Simpson EL. Jacobson ME, et al. Among authors: paller as. Dermatology. 2024;240(1):85-94. doi: 10.1159/000532054. Epub 2023 Aug 14. Dermatology. 2024. PMID: 37579728 Free PMC article. Clinical Trial.
Characterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry.
Silverberg JI, Cronin A, Jones EA, Dave SS, McLean RR, Greenberg J, Strober B, Bieber T, Gooderham M, Paller AS, Simpson EL. Silverberg JI, et al. Among authors: paller as. JAAD Int. 2024 Feb 12;15:127-130. doi: 10.1016/j.jdin.2023.11.015. eCollection 2024 Jun. JAAD Int. 2024. PMID: 38545488 Free PMC article. No abstract available.
638 results